US 2026/0250642 A1Published application

Bacteriophage

AssigneesArrowsmith Inc., National University Corporation Tokai National Higher Education and Research System

InventorsHiroki ANDO, Hideaki MATSUOKA, Koji MATSUKAWA, Yutaro ONO, Shoichi MITSUNAKA

Life of this patent

Estimating the term…

Abstract

It is an object of the present invention to provide a bacteriophage having lytic activity against Mycobacterium avium and/or Mycobacterium intracellulare. The present invention provides a bacteriophage having lytic activity against Mycobacterium avium and/or Mycobacterium intracellulare, wherein the genome of the bacteriophage contains the nucleic acid sequence of the genome of a bacteriophage identified by any of Accession Nos. NITE BP-03513 to NITE BP-03521.

Claims17

Dependent claims

A bacteriophage selected from (1) to (7) below:

(1) a bacteriophage having lytic activity against Mycobacterium avium and/or Mycobacterium intracellulare, wherein a genome of the bacteriophage:
(a) comprises a nucleic acid sequence having 90% or more identity to a nucleic acid sequence of a genome of the bacteriophage identified by Accession No. NITE BP-03513;
and (b) lacks an integrase gene and/or an immunity repressor gene;
(2) a bacteriophage having lytic activity against Mycobacterium avium and/or Mycobacterium intracellulare, wherein a genome of the bacteriophage:
(a) comprises a nucleic acid sequence having 90% or more identity to a nucleic acid sequence of a genome of the bacteriophage identified by Accession No. NITE BP-03514;
and (b) lacks an integrase gene and/or an immunity repressor gene;
(3) a bacteriophage having lytic activity against Mycobacterium avium and/or Mycobacterium intracellulare, wherein a genome of the bacteriophage:
(a) comprises a nucleic acid sequence having 90% or more identity to a nucleic acid sequence of a genome of the bacteriophage identified by Accession No. NITE BP-03515;
and (b) lacks an integrase gene and/or an immunity repressor gene;
(4) a bacteriophage having lytic activity against Mycobacterium avium and/or Mycobacterium intracellulare, wherein a genome of the bacteriophage:
(a) comprises a nucleic acid sequence having 90% or more identity to a nucleic acid sequence of a genome of the bacteriophage identified by Accession No. NITE BP-03516;
and (b) lacks an integrase gene and/or an immunity repressor gene;
(5) a bacteriophage having lytic activity against Mycobacterium avium and/or Mycobacterium intracellulare, wherein a genome of the bacteriophage:
(a) comprises a nucleic acid sequence having 90% or more identity to a nucleic acid sequence of a genome of the bacteriophage identified by Accession No. NITE BP-03517;
and (b) lacks an integrase gene and/or an immunity repressor gene;
(6) a bacteriophage having lytic activity against Mycobacterium avium and/or Mycobacterium intracellulare, wherein a genome of the bacteriophage comprises a nucleic acid sequence having 90% or more identity to a nucleic acid sequence of a genome of the bacteriophage identified by Accession No. NITE BP-03518;
and
(7) a bacteriophage having lytic activity against Mycobacterium avium and/or Mycobacterium intracellulare, wherein a genome of the bacteriophage comprises a nucleic acid sequence having 90% or more identity to a nucleic acid sequence of a genome of the bacteriophage identified by Accession No. NITE BP-03519.

15 more elements

A pharmaceutical composition comprising the bacteriophages of the following (1) to (3) and a pharmaceutically acceptable excipient:

(1) a bacteriophage having lytic activity against Mycobacterium avium and/or Mycobacterium intracellulare, wherein a genome of the bacteriophage:
(a) comprises a nucleic acid sequence having 90% or more identity to a nucleic acid sequence of a genome of the bacteriophage identified by Accession No. NITE BP-03513;
and (b) lacks an integrase gene and/or an immunity repressor gene;
(2) a bacteriophage having lytic activity against Mycobacterium avium and/or Mycobacterium intracellulare, wherein a genome of the bacteriophage:
(a) comprises a nucleic acid sequence having 90% or more identity to a nucleic acid sequence of a genome of the bacteriophage identified by Accession No. NITE BP-03514;
and (b) lacks an integrase gene and/or an immunity repressor gene;
and
(3) a bacteriophage having lytic activity against Mycobacterium avium and/or Mycobacterium intracellulare, wherein a genome of the bacteriophage comprises a nucleic acid sequence having 90% or more identity to a nucleic acid sequence of a genome of the bacteriophage identified by Accession No. NITE BP-03519.

5 more elements

Dependencies are inferred from the claim text.

patentgrep

Loading patent…

Abstract

A bacteriophage selected from (1) to (7) below:

(1) a bacteriophage having lytic activity against Mycobacterium avium and/or Mycobacterium intracellulare, wherein a genome of the bacteriophage:
(a) comprises a nucleic acid sequence having 90% or more identity to a nucleic acid sequence of a genome of the bacteriophage identified by Accession No. NITE BP-03513;
and (b) lacks an integrase gene and/or an immunity repressor gene;
(2) a bacteriophage having lytic activity against Mycobacterium avium and/or Mycobacterium intracellulare, wherein a genome of the bacteriophage:
(a) comprises a nucleic acid sequence having 90% or more identity to a nucleic acid sequence of a genome of the bacteriophage identified by Accession No. NITE BP-03514;
and (b) lacks an integrase gene and/or an immunity repressor gene;
(3) a bacteriophage having lytic activity against Mycobacterium avium and/or Mycobacterium intracellulare, wherein a genome of the bacteriophage:
(a) comprises a nucleic acid sequence having 90% or more identity to a nucleic acid sequence of a genome of the bacteriophage identified by Accession No. NITE BP-03515;
and (b) lacks an integrase gene and/or an immunity repressor gene;
(4) a bacteriophage having lytic activity against Mycobacterium avium and/or Mycobacterium intracellulare, wherein a genome of the bacteriophage:
(a) comprises a nucleic acid sequence having 90% or more identity to a nucleic acid sequence of a genome of the bacteriophage identified by Accession No. NITE BP-03516;
and (b) lacks an integrase gene and/or an immunity repressor gene;
(5) a bacteriophage having lytic activity against Mycobacterium avium and/or Mycobacterium intracellulare, wherein a genome of the bacteriophage:
(a) comprises a nucleic acid sequence having 90% or more identity to a nucleic acid sequence of a genome of the bacteriophage identified by Accession No. NITE BP-03517;
and (b) lacks an integrase gene and/or an immunity repressor gene;
(6) a bacteriophage having lytic activity against Mycobacterium avium and/or Mycobacterium intracellulare, wherein a genome of the bacteriophage comprises a nucleic acid sequence having 90% or more identity to a nucleic acid sequence of a genome of the bacteriophage identified by Accession No. NITE BP-03518;
and
(7) a bacteriophage having lytic activity against Mycobacterium avium and/or Mycobacterium intracellulare, wherein a genome of the bacteriophage comprises a nucleic acid sequence having 90% or more identity to a nucleic acid sequence of a genome of the bacteriophage identified by Accession No. NITE BP-03519.

15 more elements